Amedisys Inc: (NASD: AMED)

$11.10

0.05 (0.45%)

Volume 233,118

May 21 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		10.95 - 11.12
	
		52wk Low - High
		8.81 - 15.95
	
		Previous Close
		11.05
	
		Avg. Volume
		443,664
	
		Industry
		MED-OUTP/HM CRE
	
		Market Cap
		346.77 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.69
	
		PE (Forward)
		21.55
	
		Current Year Est.
		0.51
	
		Quarterly Earnings ESP 
		-10.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		186 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            21.55
                        
                            PEG Ratio
                            2.27
                        
                            Current Year Est.
                            0.51
                        
                            Current Quarter Estimate
                            0.10
                        
                            Most Accurate Estimate
                            0.09
                        
                            Earnings ESP 
                            -10.00%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            0.96
                        
                            Expected Earnings Growth
                            9.50%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Amedisys, Inc. is a leading multi-regional provider of home health care nursing services. They operate home care nursing offices in southern and southeastern United States.   
Full AMED Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
AMED Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.10	0.14	0.51	0.55
Number of Estimates	7	7	7	7
Low Estimate	0.03	0.12	0.46	0.44
High Estimate	0.15	0.17	0.60	NA
Year Ago EPS	0.27	0.33	1.08	0.51
EPS Growth	-61.90%	-58.44%	-52.51%	7.24%

More AMED Estimates

Average Earnings Estimates for AMED

EPS Growth for AMED

Industry Analysis

Name	Symbol	Previous Close
AMEDISYS INC	AMED	11.05
ADDUS HOMECARE	ADUS	15.51
HEALTHSOUTH CP	HLS	30.59
AMSURG CORP	AMSG	36.22
BRAIN RESOURCE	BRRZY	0.00
CHEMED CORP	CHE	68.33
CHINA CORD BLD	CO	2.86
DAVITA INC	DVA	127.07
LHC GROUP LLC	LHCG	21.98
QUEST DIAGNOSTC	DGX	60.80

Sector:Medical>> Industry:MED-OUTP/HM CRE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Huge Earnings Miss By AMED, Guides Low

May 01, 2013

Amedysis Reports 1Q Prelim Earnings

Apr 26, 2013

Amedisys Earnings Beat; Revs Lag

Mar 13, 2013

WellPoint Hikes Quarterly Dividend

Feb 22, 2013

Zacks Rank #1 Addition for Tuesday

Feb 05, 2013

Amedisys Beats EPS, Misses Rev

Nov 14, 2012

Gentiva Beats, Raises 2012 Guidance

Nov 01, 2012

Dismal Sales Projection for Amedisys

Oct 16, 2012

More AMED Zacks Commentary

Financials

EPS TTM	0.96
Sales	1,488
Net Income	-86
Price/Earnings	11.51
Price/Book	0.75
Price/Cash Flow	1.45
Price/Sales	0.24

More AMED Financials

News

Amedisys has Relatively Underperformed its Peers in the Health Care Services Industry (AMED, HMSY, ESRX, DVA, BIOS) - Financial News Network Online - News Corner

May 21, 2013

Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Amedisys Is Up 12.3% (AMED) - Comtex Smartrend(R)

May 20, 2013

Amedisys Earnings Review: 18 Days after Announcement Shares Up 12.3% (AMED) - Financial News Network Online - Earnings Lookback

May 18, 2013

American Shared Hospital Services has the Lowest Price to Book Ratio in the Health Care Services Industry (AMS, CCM, AMED) - Financial News Network Online - News Corner

May 16, 2013

Amedisys Makes a Move: Down 1.7% - Financial News Network Online - Market Movers

May 15, 2013

RadNet Ranks the Lowest in Terms of P/E Ratio in the Health Care Services Industry (RDNT, GTIV, AMED) - Financial News Network Online - News Corner

May 15, 2013

Gentiva Health Services has the Highest Beta in the Health Care Services Industry (GTIV, AMED, AHS) - Financial News Network Online - News Corner

May 13, 2013

Lowest PEG Ratio in the Health Care Services Industry Detected for Amedisys (AMED, AIRM, GTIV) - Financial News Network Online - News Corner

May 10, 2013

See All News Stories on AMED

Broker Recommendations

Current ABR	3.00
ABR (Last Week)	3.00
# of recs in ABR	7
Average Target Price	10.29
Industry Rank by ABR	186 out of 265
Rank in Industry	13 out of 16

More AMED Broker Recommendations

Day Low - High	10.95 - 11.12
52wk Low - High	8.81 - 15.95
Previous Close	11.05
Avg. Volume	443,664
Industry	MED-OUTP/HM CRE
Market Cap	346.77 M
Div - Yield	0.00 - 0.00
Beta	0.69
PE (Forward)	21.55
Current Year Est.	0.51
Quarterly Earnings ESP	-10.00%

PE (Forward)	21.55
PEG Ratio	2.27
Current Year Est.	0.51
Current Quarter Estimate	0.10
Most Accurate Estimate	0.09
Earnings ESP	-10.00%
Next Earnings Report Date	08-06-2013
EPS Last Year	0.96
Expected Earnings Growth	9.50%

Username: Password:

Remember me [?]

Amedisys Inc: (NASD: AMED)

$11.10

0.05 (0.45%)

Volume 233,118

May 21 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description